Amisulpride Safety and Outcomes in Chinese Patients With Schizophrenia
About this title
Read the official source — NCT01795183Researchers studied AMISULPRIDE to find out how it affected psychotic symptoms in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers studied AMISULPRIDE to find out how it affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- BeijingSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 316
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01795183
- Official title
Show the full official title
The Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia - A Prospective Open-Label Multicenter Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Beijing
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied AMISULPRIDE to find out how it affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Sanofi.
Did this study involve medication?
Yes. The study involved medication, including AMISULPRIDE.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
